AVITA Medical Inc. is a commercial stage regenerative tissue company in the United States, Australia, and the United Kingdom. The company is headquartered in Valencia, California.
| Revenue (TTM) | $75.63M |
| Gross Profit (TTM) | $61.68M |
| EBITDA | $-32.76M |
| Operating Margin | -31.60% |
| Return on Equity | -1746.00% |
| Return on Assets | -41.60% |
| Revenue/Share (TTM) | $2.52 |
| Book Value | $-0.90 |
| Price-to-Book | 11.77 |
| Price-to-Sales (TTM) | 3.23 |
| EV/Revenue | 3.704 |
| EV/EBITDA | -6.17 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 17.80% |
| Shares Outstanding | $30.93M |
| Float | $30.47M |
| % Insiders | 1.98% |
| % Institutions | 15.56% |
Volatility is currently contracting
AVITA Medical's PermeaDerm study shows 70% lower product cost than allograft, with comparable clinical outcomes and a 96% reduction in preparation time.
Avita Medical NASDAQ: RCEL reported second-quarter 2026 revenue of $21.7 million, up 13% sequentially from $19.3 million in the first quarter and 18% from $18.4 million a year earlier, as the wound-care company cited growth across its product portfolio and in U.S. and international markets.
Avita Medical NASDAQ: RCEL expects continued sequential revenue growth and aims to reach cash flow breakeven in the fourth quarter of 2025, President and CEO Cary Vance said at the Canaccord 46th Annual Boston Growth Conference.
AVITA Medical, Inc. (RCEL) Shareholder/Analyst Call Transcript
VALENCIA, Calif., Aug. 09, 2026 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions, invites shareholders and prospective investors to attend its investor webinar briefing and presentation by Cary Vance, President and Chief Executive Officer, and David O'Toole, Chief Financial Officer, on August 12, 2026, at 4:00 p.m.
VALENCIA, Calif., Aug. 07, 2026 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions, today announced it will be participating at the Canaccord Genuity 46th Annual Growth Conference in Boston, taking place August 11–13, 2026.
Avita Medical NASDAQ: RCEL reported second-quarter 2026 revenue of $21.7 million, up 18% from a year earlier and 13% sequentially, as growth in its RECELL wound-care product and newer portfolio offerings supported results.
AVITA Medical, Inc. (RCEL) Q2 2026 Earnings Call Transcript
VALENCIA, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- AVITA Medical®, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions (“AVITA Medical,” or the “Company”), today reported financial results for the second quarter ended June 30, 2026.
VALENCIA, Calif., July 14, 2026 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (“AVITA Medical,” or the “Company”), a leading therapeutic acute wound care company delivering transformative solutions, today announced that it will report its second quarter 2026 financial results after the close of the U.S. financial markets on Thursday, August 6, 2026.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on RCEL and any ticker you trade — then tracks every position and per-strategy win rate.
